#USA #National Harbor #Kyowa Hakko #Cognizin® Citicoline #Neuromuscular Health

The Promise of Cognizin® Citicoline in Neuromuscular Health

Recent advancements in preclinical research indicate that Cognizin® Citicoline, produced by Kyowa Hakko, could significantly contribute to neuromuscular health by enhancing the formation of neuromuscular junctions (NMJs). NMJs are essential interfaces where motor neurons connect with skeletal muscle fibers, playing a vital role in muscle activation and coordination. Ongoing studies suggest that preserving the integrity of NMJs is crucial for maintaining muscle strength and overall performance, particularly as we age.

The deterioration of NMJs is increasingly recognized as a significant factor leading to muscle weakness and reduced physical performance in older adults. Therefore, understanding and improving NMJ functionality could be beneficial for athletes and seniors alike, making this a particularly compelling area of research for both sports nutrition and healthy aging formulations.

The recent investigation was conducted by researchers at the Institute of Health Sciences, part of Kirin Holdings Company, which oversees Kyowa Hakko. Using a specialized in vitro neuromuscular cell model, researchers measured Cognizin's impact on NMJ formation through gene expression analysis and immunofluorescence imaging. Key markers for NMJ development, such as acetylcholine receptor (AChR) clustering, were analyzed to determine the effectiveness of Cognizin in enhancing NMJ integrity.

Karen Todd, Vice President of Global Brand Marketing at Kyowa Hakko USA, emphasized the growing consumer and manufacturer demand for scientifically backed cognitive health ingredients. She stated, "As Cognizin continues to set itself apart, it's crucial that our ongoing investments in rigorous clinical and preclinical science provide formulators with validated evidence to create products that consumers can trust. This research opens doors to new and exciting application areas that are only beginning to unfold."

The findings from this research will be showcased during the Sports/Performance Nutrition Poster Session at the American Society for Nutrition's NUTRITION 2026 conference, scheduled for July 27 in National Harbor, Maryland. Lead author Chihiro Ono of Kirin Holdings will present their poster detailing how citicoline may enhance the clustering of AChRs, facilitating better NMJ formation when cultured with neurons and skeletal muscle cells.

This new line of research underscores Kyowa Hakko's commitment to pioneering studies that advance Cognizin's scientific foundations. For manufacturers of supplements and functional foods, the findings suggest a new opportunity to develop products aimed at improving performance and health as people age.

About Cognizin® Citicoline

Developed by Kyowa Hakko Bio Co., Ltd., Cognizin® Citicoline is a clinically patented compound, backed by over 35 years of research. Known for its role in enhancing cognitive functions such as mental energy, focus, and memory, Cognizin is produced through advanced fermentation technology, ensuring high purity and quality. It is also recognized for being allergen-free, stable, and GRAS (Generally Recognized As Safe).

As the world increasingly recognizes the importance of maintaining cognitive health, studies like these not only spotlight the potential applications of Cognizin in neuromuscular health but also enhance its credibility in the nutraceutical and wellness sectors. More about Cognizin can be found at Cognizin.com and Kyowa-USA.com.

This research represents a substantial step forward in storing neuromuscular health, marking a pivotal chapter in Cognizin's ongoing narrative of innovation and efficacy.